Table 1 General characteristics of the patient with moderate-to-severe psoriasis.
Variables | Whole period (2014–2020) | By year | ||||||
|---|---|---|---|---|---|---|---|---|
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | ||
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Total | 57,139 | 13,801 | 14,658 | 15,691 | 16,289 | 16,844 | 17,646 | 16,294 |
Sex | ||||||||
 Male | 34,760 (60.8) | 8824 (63.9) | 9220 (62.9) | 9846 (62.7) | 10,321 (63.4) | 10,767 (63.9) | 11,267 (63.9) | 10,469 (64.3) |
 Female | 22,379 (39.2) | 4977 (36.1) | 5438 (37.1) | 5845 (37.3) | 5968 (36.6) | 6077 (36.1) | 6379 (36.1) | 5825 (35.7) |
Age group | ||||||||
 20–29 | 6324 (11.1) | 1099 (8.0) | 1143 (7.8) | 1279 (8.2) | 1336 (8.2) | 1440 (8.5) | 1506 (8.5) | 1459 (9.0) |
 30–39 | 9213 (16.1) | 2274 (16.5) | 2308 (15.7) | 2437 (15.5) | 2477 (15.2) | 2522 (15.0) | 2506 (14.2) | 2251 (13.8) |
 40–49 | 12,192 (21.3) | 3224 (23.4) | 3297 (22.5) | 3400 (21.7) | 3620 (22.2) | 3602 (21.4) | 3699 (21.0) | 3401 (20.9) |
 50–59 | 13,461 (23.6) | 3633 (26.3) | 3791 (25.9) | 4006 (25.5) | 4100 (25.2) | 4195 (24.9) | 4429 (25.1) | 3989 (24.5) |
 60–69 | 9457 (16.6) | 2051 (14.9) | 2419 (16.5) | 2725 (17.4) | 2881 (17.7) | 3069 (18.2) | 3298 (18.7) | 3185 (19.5) |
 80–79 | 4962 (8.7) | 1237 (9.0) | 1347 (9.2) | 1462 (9.3) | 1474 (9.0) | 1540 (9.1) | 1622 (9.2) | 1515 (9.3) |
 80- | 1530 (2.7) | 283 (2.1) | 353 (2.4) | 382 (2.4) | 401 (2.5) | 476 (2.8) | 586 (3.3) | 494 (3.0) |
Income | ||||||||
 Medical Aid | 2291 (4.0) | 589 (4.3) | 635 (4.3) | 693 (4.4) | 709 (4.4) | 738 (4.4) | 797 (4.5) | 744 (4.6) |
 Lowesta | 11,605 (20.3) | 2682 (19.4) | 2802 (19.1) | 3042 (19.4) | 3213 (19.7) | 3394 (20.1) | 3763 (21.3) | 3241 (19.9) |
 Mid-lowa | 11,785 (20.6) | 2932 (21.2) | 3072 (21.0) | 3263 (20.8) | 3263 (20) | 3467 (20.6) | 3498 (19.8) | 3400 (20.9) |
 Mid-higha | 14,745 (25.8) | 3557 (25.8) | 3811 (26.0) | 3948 (25.2) | 4220 (25.9) | 4209 (25.0) | 4362 (24.7) | 3982 (24.4) |
 Highesta | 16,713 (29.2) | 4041 (29.3) | 4338 (29.6) | 4745 (30.2) | 4884 (30.0) | 5036 (29.9) | 5226 (29.6) | 4927 (30.2) |
Residence | ||||||||
 Metropolitan | 38,981 (68.2) | 9273 (67.2) | 9803 (66.9) | 10,875 (69.3) | 11,254 (69.1) | 1152 (6.8) | 12,126 (68.7) | 11,459 (70.3) |
 Others | 18,158 (31.8) | 4528 (32.8) | 4855 (33.1) | 4,816 (30.7) | 5,035 (30.9) | 5192 (30.8) | 5520 (31.3) | 4835 (29.7) |
Biologics use | ||||||||
 Yes | 3464 (6.1) | 444 (3.2) | 554 (3.8) | 787 (5.0) | 1,062 (6.5) | 1,607 (9.5) | 2341 (13.3) | 3123 (19.2) |
 No | 53,675 (93.9) | 13,357 (96.8) | 14,104 (96.2) | 14,904 (95) | 15,227 (93.5) | 15,237 (90.5) | 15,305 (86.7) | 13,171 (80.8) |
RCP* | ||||||||
 Enrolled | 2327 (4.1) | – | – | – | 570 (3.5) | 1039 (6.2) | 1626 (9.2) | 2249 (13.8) |
 Not enrolled | 54,812 (95.9) | – | – | – | 15,719 (96.5) | 15,805 (93.8) | 16,020 (90.8) | 14,045 (86.2) |
Mortality | 445 (0.8) | 60 (0.4) | 57 (0.4) | 56 (0.4) | 64 (0.4) | 70 (0.4) | 70 (0.4) | 68 (0.4) |
